A final-phase trial of Hutchison China Meditech’s (HCM) cancer drug fruquintinib has failed to demonstrate “a statistically significant increase in overall survival” amongst advanced non-small-cell lung cancer patients in China.
IC TIP:
Buy
at
4,880p